Key facts
- Neogap’s last known valuation is $12.7M (Nov 2023).
- It has raised $20.9M; the latest was Later Stage VC ($9.6M) in Feb 2026.
- Notable investors include European Innovation Council, Swedish-American Chamber of Commerce - New York (SACCNY), 3T Invest, European Innovation Council (Belgium), Northislet — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Neogap
- ·The full record, as it builds
Funding rounds
No funding rounds for Neogap are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neogap
Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer. The company's product identifies optimal neoantigens to target, activate and multiply T-lymphocytes with the purpose of eradicating cancer, enabling cancer patients to recover from the disease.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2016
- Employees
- 25
- Website
- neogap.se/
- Ownership
- Privately Held (backing)
Neogap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neogap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neogap in its N-PORT filings yet. We sweep new filings monthly.